Winton Group
ARCT icon

Winton Group’s Arcturus Therapeutics ARCT Stock Holding History

Winton Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,389
Closed -$359K – 604
2023
Q4 		$359K Sell
11,389
-3,282
-22% -$78K 0.03% 477
2023
Q3 		$375K Buy
14,671
+5,164
+54% +$159K 0.03% 443
2023
Q2 		$273K Buy
+9,507
New +$259K 0.02% 559
2021
Q4 		– Sell
-4,663
Closed -$223K – 1019
2021
Q3 		$223K Sell
4,663
-6,501
-58% -$291K 0.01% 1202
2021
Q2 		$378K Buy
11,164
+500
+5% +$16.9K 0.02% 1065
2021
Q1 		$440K Buy
+10,664
New +$636K 0.03% 955

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winton Group's ARCT Position: Q1 2024 in Review

Winton Group sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 11,389 shares — an estimated $359K sold.

Winton Group first reported a position in ARCT in Q1 2021 and held it in 6 quarters. The position peaked at $440K in Q1 2021. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Winton Group reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Winton Group sold 11,389 Arcturus Therapeutics shares in Q1 2024, an estimated $359K.
  • Winton Group first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 6 quarters.
  • Winton Group's Arcturus Therapeutics position peaked at $440K in Q1 2021.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Winton Group's 13F filing for Q1 2024, filed 14 May 2024.